Citius Pharmaceuticals Inc (CTXR) - Total Liabilities
Based on the latest financial reports, Citius Pharmaceuticals Inc (CTXR) has total liabilities worth $63.46 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CTXR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Citius Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Citius Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Citius Pharmaceuticals Inc total assets.
Citius Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Citius Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
Turkey | TL886.75 Million |
|
Vietnam Sun Corp
VN:VNS
|
Vietnam | ₫675.69 Billion |
|
ENERSIDE ENERGY EO -01
F:9O8
|
Germany | €83.98 Million |
|
Greater Than AB
ST:GREAT
|
Sweden | Skr47.90 Million |
|
Greenbriar Capital Corp
V:GRB
|
Canada | CA$17.41 Million |
|
Farmaceutica R
RO:RMAH
|
Romania | RON303.69 Million |
|
Omnisystem Co.Ltd
KQ:057540
|
Korea | ₩31.80 Billion |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
USA | $5.04 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Citius Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Citius Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Citius Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Citius Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Citius Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $53.41 Million | +25.52% |
| 2024-09-30 | $42.55 Million | +249.35% |
| 2023-09-30 | $12.18 Million | +15.20% |
| 2022-09-30 | $10.57 Million | +9.61% |
| 2021-09-30 | $9.65 Million | -4.52% |
| 2020-09-30 | $10.10 Million | +119.26% |
| 2019-09-30 | $4.61 Million | +44.68% |
| 2018-09-30 | $3.18 Million | +28.98% |
| 2017-09-30 | $2.47 Million | -52.37% |
| 2016-09-30 | $5.18 Million | +276.54% |
| 2015-09-30 | $1.38 Million | -40.13% |
| 2014-09-30 | $2.30 Million | +15548.54% |
| 2013-09-30 | $14.69K | -68.04% |
| 2012-09-30 | $45.98K | +91.17% |
| 2011-09-30 | $24.05K | -- |
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-… Read more